Adults: 1 tab once daily. Genotype 1: Treatment-naïve without cirrhosis or with compensated cirrhosis (Child-Pugh A), or treatment-experienced without cirrhosis: treat for 12wks; treatment-naïve without cirrhosis who have pre-treatment HCV RNA <6 million IU/mL: can be considered for 8wks. Treatment-experienced with compensated cirrhosis: treat for 24wks; can be considered for 12wks + ribavirin (if eligible). Treatment-naïve and -experienced with decompensated cirrhosis (Child-Pugh B or C): treat for 12wks + ribavirin (see full labeling). Genotype 1 or 4: Treatment-naïve and -experienced liver transplant recipients without cirrhosis or with compensated cirrhosis: treat for 12wks + ribavirin. Genotype 4, 5, 6: Treatment-naïve and -experienced without cirrhosis or with compensated cirrhosis: treat for 12wks. HCV/HIV-1 co-infection: follow same dosage schedule. See full labeling.
Children: <18yrs: Not established.

Adults: Take with food. ≥18yrs: 2 tabs once
daily in the AM for 12wks with ribavirin. Treatment-naive (with ribavirin intolerance): may
consider administering without ribavirin for 12wks.
Children: <18yrs: Not established

8Indicated for the treatment of chronic HCV genotype 1a (in combination with ribavirin) or 1b infection without cirrhosis or with compensated cirrhosis. Contraindicated in moderate-to-severe hepatic impairment.

Not an inclusive list of
medications, official indications and/or dosing details. For dose adjustments or reductions,
please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.